Abstract #1844

Accuracy of IMPROD biparametric pre-biopsy MRI for prostate cancer detection in correlation with whole mount prostatectomy sections: implications for focal therapy (IMPROD trial, #opensourcetrial)

Harri Merisaari¹, Pekka Taimen², Otto Ettala², Peter Boström², Ileana Montoya Perez¹, Janne Verho¹, Aida Kiviniemi¹, Kari Syvänen², Esa Kähkönen², Tapio Pahikkala¹, Jani Saunavaara², Hannu Aronen¹, and Ivan Jambor^1,3

¹University of Turku, Turku, Finland, ²Turku University Hospital, Turku, Finland, ³Icahn School of Medicine at Mount Sinai, New York, NY, United States

In this prospective single institutional trial(NCT01864135), we evaluated the accuracy of a unique prostate MRI acquisition and reporting protocol, IMPROD biparametric MRI, in men with a clinical suspicion of prostate cancer who were subsequently diagnosed with prostate cancer and underwent prostatectomy. IMPROD biparametric MRI correctly detected 75% (75/99) of prostate cancer lesions with diameter ≥5 mm or any Gleason grade 4, and only two of the missed prostate cancer lesions had Gleason score >3+4. However, only a limited accuracy on isotropic voxel level was achieved potentially limiting focal therapy planning. All data are freely are available at the following address: http://petiv.utu.fi/improd

This abstract and the presentation materials are available to members only; a login is required.

Join Here